Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Immunovant, Inc. (IMVT) had Stock-Based Compensation of $18.51M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-120.61M |
|
-- |
|
-- |
|
$127.22M |
|
$-127.22M |
|
$7.52M |
|
$-119.70M |
|
$-119.70M |
|
$-120.61M |
|
$-120.61M |
|
$-120.61M |
|
$-120.61M |
|
$-127.22M |
|
$-127.12M |
|
170.87M |
|
170.87M |
|
$-0.71 |
|
$-0.71 |
|
| Balance Sheet Financials | |
$651.76M |
|
$0.74M |
|
$9.68M |
|
$661.44M |
|
$52.90M |
|
-- |
|
-- |
|
$52.90M |
|
$608.54M |
|
$608.54M |
|
$608.54M |
|
171.07M |
|
| Cash Flow Statement Financials | |
$-117.41M |
|
-- |
|
$2.92M |
|
$713.97M |
|
$598.91M |
|
$-115.06M |
|
|
Stock-Based Compensation |
$18.51M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-117.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.82% |
|
-19.82% |
|
-18.23% |
|
-19.82% |
|
$3.56 |
|
$-0.69 |
|
$-0.69 |
|